Panagora Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Panagora Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Sell	1,388 -150,061	-99%	-$22.3M	﹤0.01%	1087
2026 Q1	$20M	Buy	+151,449	New	+$20.1M	0.07%	232
2025 Q4	–	Sell	-1,559	Closed	-$219K	–	1230
2025 Q3	$219K	Buy	+1,559	New	+$211K	﹤0.01%	1069
2024 Q4	–	Sell	-7,257	Closed	-$836K	–	1215
2024 Q3	$836K	Sell	7,257 -389	-5%	-$53.3K	﹤0.01%	778
2024 Q2	$1.05M	Sell	7,646 -259,951	-97%	-$35.6M	0.01%	709
2024 Q1	$36.9M	Buy	267,597 +197,249	+280%	+$26.9M	0.19%	120
2023 Q4	$9.27M	Buy	70,348 +46,245	+192%	+$5.32M	0.05%	235
2023 Q3	$2.71M	Buy	24,103 +8,048	+50%	+$847K	0.02%	436
2023 Q2	$1.51M	Buy	16,055 +5,290	+49%	+$517K	0.01%	646
2023 Q1	$1.09M	Sell	10,765 -204	-2%	-$21.2K	0.01%	804
2022 Q4	$1.31M	Sell	10,969 -2,540	-19%	-$298K	0.01%	775
2022 Q3	$1.44M	Hold	13,509	–	–	0.01%	715
2022 Q2	$1.32M	Hold	13,509	–	–	0.01%	770
2022 Q1	$1.27M	Hold	13,509	–	–	0.01%	835
2021 Q4	$1.15M	Sell	13,509 -1,264	-9%	-$116K	0.01%	853
2021 Q3	$1.42M	Sell	14,773 -109	-0.7%	-$10.3K	0.01%	813
2021 Q2	$1.45M	Buy	14,882 +4,609	+45%	+$442K	0.01%	826
2021 Q1	$999K	Buy	10,273 +4,067	+66%	+$426K	0.01%	1023
2020 Q4	$595K	Sell	6,206 -133	-2%	-$12.8K	﹤0.01%	1162
2020 Q3	$610K	Buy	6,339 +6,049	+2,086%	+$700K	﹤0.01%	1087
2020 Q2	$35K	Buy	290 +58	+25%	+$6.41K	﹤0.01%	2054
2020 Q1	$20K	Buy	+232	New	+$22.7K	﹤0.01%	2045
2019 Q3	–	Sell	-900	Closed	-$76K	–	2570
2019 Q2	$76K	Hold	900	–	–	﹤0.01%	2024
2019 Q1	$79K	Hold	900	–	–	﹤0.01%	1947
2018 Q4	$64K	Hold	900	–	–	﹤0.01%	1911
2018 Q3	$111K	Hold	900	–	–	﹤0.01%	1823
2018 Q2	$88K	Hold	900	–	–	﹤0.01%	1882
2018 Q1	$75K	Hold	900	–	–	﹤0.01%	1923
2017 Q4	$70K	Hold	900	–	–	﹤0.01%	1979
2017 Q3	$55K	Hold	900	–	–	﹤0.01%	2036
2017 Q2	$41K	Hold	900	–	–	﹤0.01%	2116
2017 Q1	$39K	Hold	900	–	–	﹤0.01%	2059
2016 Q4	$35K	Hold	900	–	–	﹤0.01%	2148
2016 Q3	$46K	Sell	900 -29,343	-97%	-$1.46M	﹤0.01%	2126
2016 Q2	$1.38M	Sell	30,243 -7,125	-19%	-$328K	0.01%	996
2016 Q1	$1.48M	Buy	37,368 +32,780	+714%	+$1.3M	0.01%	967
2015 Q4	$260K	Hold	4,588	–	–	﹤0.01%	1503
2015 Q3	$183K	Buy	4,588 +2,971	+184%	+$144K	﹤0.01%	1630
2015 Q2	$77K	Buy	1,617 +717	+80%	+$30.4K	﹤0.01%	2026
2015 Q1	$36K	Hold	900	–	–	﹤0.01%	2133
2014 Q4	$20K	Hold	900	–	–	﹤0.01%	2171
2014 Q3	$14K	Sell	900 -1,060	-54%	-$15.8K	﹤0.01%	2203
2014 Q2	$29K	Buy	1,960 +1,060	+118%	+$15K	﹤0.01%	2188
2014 Q1	$14K	Hold	900	–	–	﹤0.01%	2262
2013 Q4	$8K	Sell	900 -600	-40%	-$5.86K	﹤0.01%	2144
2013 Q3	$17K	Hold	1,500	–	–	﹤0.01%	2208
2013 Q2	$20K	Buy	+1,500	New	+$18.4K	﹤0.01%	2177

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Panagora Asset Management's NBIX Position: Q2 2026 in Review

Panagora Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 99% in Q2 2026, selling an estimated $22.3M and leaving 1,388 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Panagora Asset Management first reported a position in NBIX in Q2 2013 and has held it in 47 quarters since. The position peaked at $36.9M in Q1 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Panagora Asset Management held 1,388 shares of Neurocrine Biosciences worth $234K as of Q2 2026.
Panagora Asset Management sold 150,061 Neurocrine Biosciences shares in Q2 2026, an estimated $22.3M.
Neurocrine Biosciences made up ﹤0.01% of Panagora Asset Management's portfolio in Q2 2026, its #1087 holding.
Panagora Asset Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 47 quarters since.
Panagora Asset Management's Neurocrine Biosciences position peaked at $36.9M in Q1 2024.
772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.